BACKGROUND: Clinically, human immunodeficiency virus type 1 (HIV-1) pol sequences are used to evaluate for drug resistance. These data can also be used to evaluate transmission networks and help describe factors associated with transmission risk. METHODS: HIV-1 pol sequences from participants at 5 sites in the CFAR Network of Integrated Clinical Systems (CNICS) cohort from 2000-2009 were analyzed for genetic relatedness. Only the first available sequence per participant was included. Inferred transmission networks ("clusters") were defined as ≥2 sequences with ≤1.5% genetic distance. Clusters including ≥3 patients ("networks") were evaluated for clinical and demographic associations. RESULTS: Of 3697 sequences, 24% fell into inferred clusters: 155 clusters of 2 individuals ("dyads"), 54 clusters that included 3-14 individuals ("networks"), and 1 large cluster that included 336 individuals across all study sites. In multivariable analyses, factors associated with being in a cluster included not using antiretroviral (ARV) drugs at time of sampling (P < .001), sequence collected after 2004 (P < .001), CD4 cell count >350 cells/mL (P < .01), and viral load 10,000-100,000 copies/mL (P < .001) or >100,000 copies/mL (P < .001). In networks, women were more likely to cluster with other women (P < .001), and African Americans with other African Americans (P < .001). CONCLUSIONS: Molecular epidemiology can be applied to study HIV transmission networks in geographically and demographically diverse cohorts. Clustering was associated with lack of ARV use and higher viral load, implying transmission may be interrupted by earlier diagnosis and treatment. Observed female and African American networks reinforce the importance of diagnosis and prevention efforts targeted by sex and race.
BACKGROUND: Clinically, human immunodeficiency virus type 1 (HIV-1) pol sequences are used to evaluate for drug resistance. These data can also be used to evaluate transmission networks and help describe factors associated with transmission risk. METHODS:HIV-1 pol sequences from participants at 5 sites in the CFAR Network of Integrated Clinical Systems (CNICS) cohort from 2000-2009 were analyzed for genetic relatedness. Only the first available sequence per participant was included. Inferred transmission networks ("clusters") were defined as ≥2 sequences with ≤1.5% genetic distance. Clusters including ≥3 patients ("networks") were evaluated for clinical and demographic associations. RESULTS: Of 3697 sequences, 24% fell into inferred clusters: 155 clusters of 2 individuals ("dyads"), 54 clusters that included 3-14 individuals ("networks"), and 1 large cluster that included 336 individuals across all study sites. In multivariable analyses, factors associated with being in a cluster included not using antiretroviral (ARV) drugs at time of sampling (P < .001), sequence collected after 2004 (P < .001), CD4 cell count >350 cells/mL (P < .01), and viral load 10,000-100,000 copies/mL (P < .001) or >100,000 copies/mL (P < .001). In networks, women were more likely to cluster with other women (P < .001), and African Americans with other African Americans (P < .001). CONCLUSIONS: Molecular epidemiology can be applied to study HIV transmission networks in geographically and demographically diverse cohorts. Clustering was associated with lack of ARV use and higher viral load, implying transmission may be interrupted by earlier diagnosis and treatment. Observed female and African American networks reinforce the importance of diagnosis and prevention efforts targeted by sex and race.
Authors: Alexandra M Oster; Cyprian Wejnert; Leandro A Mena; Kim Elmore; Holly Fisher; James D Heffelfinger Journal: Sex Transm Dis Date: 2013-03 Impact factor: 2.830
Authors: Robert J Gifford; Tulio de Oliveira; Andrew Rambaut; Oliver G Pybus; David Dunn; Anne-Mieke Vandamme; Paul Kellam; Deenan Pillay Journal: J Virol Date: 2007-09-26 Impact factor: 5.103
Authors: Edward R Cachay; Niousha Moini; Sergei L Kosakovsky Pond; Rick Pesano; Yolanda S Lie; Heidi Aiem; David M Butler; Scott Letendre; Wm Christopher Mathews; Davey M Smith Journal: Open AIDS J Date: 2007-10-22
Authors: Stéphane Le Vu; Oliver Ratmann; Valerie Delpech; Alison E Brown; O Noel Gill; Anna Tostevin; Christophe Fraser; Erik M Volz Journal: Epidemics Date: 2017-10-20 Impact factor: 4.396
Authors: Joel O Wertheim; Alexandra M Oster; Angela L Hernandez; Neeraja Saduvala; M Cheryl Bañez Ocfemia; H Irene Hall Journal: AIDS Res Hum Retroviruses Date: 2016-05-19 Impact factor: 2.205
Authors: Rebecca Rose; Susanna L Lamers; James J Dollar; Mary K Grabowski; Emma B Hodcroft; Manon Ragonnet-Cronin; Joel O Wertheim; Andrew D Redd; Danielle German; Oliver Laeyendecker Journal: AIDS Res Hum Retroviruses Date: 2016-12-13 Impact factor: 2.205
Authors: Mi Young Ahn; Joel O Wertheim; Woo Joo Kim; Shin-Woo Kim; Jin Soo Lee; Hea Won Ann; Yongduk Jeon; Jin Young Ahn; Je Eun Song; Dong Hyun Oh; Yong Chan Kim; Eun Jin Kim; In Young Jung; Moo Hyun Kim; Wooyoung Jeong; Su Jin Jeong; Nam Su Ku; June Myung Kim; Davey M Smith; Jun Yong Choi Journal: AIDS Res Hum Retroviruses Date: 2017-03-27 Impact factor: 2.205
Authors: Dana K Pasquale; Irene A Doherty; Lynne A Sampson; Stephane Hué; Peter A Leone; Joseph Sebastian; Sue L Ledford; Joseph J Eron; William C Miller; Ann M Dennis Journal: J Acquir Immune Defic Syndr Date: 2018-08-01 Impact factor: 3.731
Authors: David N Burns; Victor DeGruttola; Christopher D Pilcher; Mirjam Kretzschmar; Christopher M Gordon; Elizabeth H Flanagan; Christopher Duncombe; Myron S Cohen Journal: AIDS Res Hum Retroviruses Date: 2014-02-11 Impact factor: 2.205
Authors: Philip A Chan; Joseph W Hogan; Austin Huang; Allison DeLong; Marco Salemi; Kenneth H Mayer; Rami Kantor Journal: J Acquir Immune Defic Syndr Date: 2015-12-01 Impact factor: 3.731